Here we found that GZD824 treatment significantly decreased proliferation of both human Ph+ and Ph– pre-B ALL cells, indicating that GZD824's anti-tumor activity in pre-B ALL is partly independent of BCR-ABL kinase activity. Here, ABL1 is linked to acute lymphoblastic leukemia.